SL
CPRX

Salomon & Ludwin’s Catalyst Pharmaceutical CPRX Stock Holding History

Salomon & Ludwin’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1K Buy
1,942
+76
+4% +$2.24K 0.01% 457
2026
Q1 		$46.1K Buy
1,866
+1,093
+141% +$26K ﹤0.01% 523
2025
Q4 		$17.6K Sell
773
-175
-18% -$3.9K ﹤0.01% 1002
2025
Q3 		$19.8K Buy
+948
New +$19.5K ﹤0.01% 824

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Salomon & Ludwin's CPRX Position: Q2 2026 in Review

Salomon & Ludwin increased its Catalyst Pharmaceutical (CPRX) stake by 4.1% in Q2 2026, buying an estimated $2.24K and bringing the position to 1,942 shares worth $61.1K. The position accounts for 0.01% of the portfolio, ranked #457.

Salomon & Ludwin first reported a position in CPRX in Q3 2025 and has held it in 4 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Salomon & Ludwin held 1,942 shares of Catalyst Pharmaceutical worth $61.1K as of Q2 2026.
  • Salomon & Ludwin bought 76 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.24K.
  • Catalyst Pharmaceutical made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #457 holding.
  • Salomon & Ludwin first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.